PTC Therapeutics, Inc. (PTCT)
NASDAQ: PTCT · Real-Time Price · USD
70.26
+1.04 (1.50%)
At close: Apr 28, 2026, 4:00 PM EDT
72.20
+1.94 (2.76%)
After-hours: Apr 28, 2026, 5:37 PM EDT
PTC Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for PTC Therapeutics stock have an average target of 80.65, with a low estimate of 50 and a high estimate of 119. The average target predicts an increase of 14.79% from the current stock price of 70.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PTC Therapeutics stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 7 | 6 | 7 | 7 | 7 | 7 |
| Hold | 4 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 2 | 2 | 1 | 1 | 1 |
| Total | 17 | 17 | 18 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $91 → $76 | Strong Buy → Hold | Downgrades | $91 → $76 | +8.17% | Mar 30, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $90 → $92 | Buy | Maintains | $90 → $92 | +30.94% | Feb 23, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $93 → $86 | Buy | Maintains | $93 → $86 | +22.40% | Feb 20, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $87 → $82 | Hold | Maintains | $87 → $82 | +16.71% | Feb 20, 2026 |
| B of A Securities | B of A Securities | Strong Buy Maintains $97 → $93 | Strong Buy | Maintains | $97 → $93 | +32.37% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
1.02B
from 1.73B
Decreased by -41.24%
Revenue Next Year
1.20B
from 1.02B
Increased by 17.70%
EPS This Year
-0.78
from 7.78
EPS Next Year
1.05
from -0.78
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.5B | 2.0B | ||||||
| Avg | 1.0B | 1.2B | ||||||
| Low | 695.1M | 770.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -14.4% | 98.9% | ||||||
| Avg | -41.2% | 17.7% | ||||||
| Low | -59.8% | -24.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.68 | 8.62 | ||||||
| Avg | -0.78 | 1.05 | ||||||
| Low | -2.90 | -4.69 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -65.6% | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.